Livtencity is an orally bioavailable anti-CMV compound that targets and inhibits the UL97 protein kinase and its natural substrates. The Food and Drug Administration (FDA) has approved Livtencity ...
ROCKVILLE, Md. & SAN DIEGO--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, ...
- LIVTENCITY Is the First and Only Inhibitor of CMV-specific UL97 Protein Kinase Approved in China for the Treatment of Adults With Post-transplant CMV Infection/Disease Refractory* to Conventional ...
− If Approved, Maribavir Will Be the First and Only Treatment Indicated for Post-Transplant Cytomegalovirus (CMV) Infection in Those That Are Refractory, With or Without Resistance (R/R) − NDA based ...
Recent $11.3 million grant from the California Institute for Regenerative Medicine (CIRM) intended to fund the Phase 1 clinical trial at City of Hope; the Investigational New Drug application for ...
Cytomegalovirus (CMV) is a common virus that most adults are exposed to at some point in their lives, and over half of American adults have been infected by age 40. A healthy immune system can keep ...
Cytomegalovirus infections companies working in the market are ModernaTX, Inc., Merck Sharp & Dohme LLC, GlaxoSmithKline, AlloVir, and others. (Albany, USA) DelveInsight’s Cytomegalovirus Infections ...
Historically, it is a very difficult disease to treat and current treatment options offer limited benefit to extend survival,” added Mitchell. “The results demonstrated with CMV-specific dendritic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback